Telix already holds roughly 60 percent of the U.S. PSMA-PET market through Illuccix, yet that dominance is almost entirely tied to a single clinical workflow: diagnosing and staging prostate cancer ahead of conventional surgery or radiation. The letters of intent signed with EDAP TMS and Profound Medical signal a deliberate push to embed Gozellix and Illuccix into a second, structurally different market — image-guided ablation — where neither robotic HIFU nor MRI-guided TULSA has achieved anything close to mainstream adoption. That asymmetry is the strategic bet: Telix is not defending existing share, it is trying to colonize a workflow before its competitors can.
The commercial logic is straightforward even if the clinical evidence remains preliminary. EDAP’s Focal One platform has a growing but still limited global installed base, and Profound’s TULSA-PRO is cleared across major markets yet rarely appears in U.S. treatment guidelines. Both technologies live or die on their ability to demonstrate that tissue selection and ablation boundaries are precise enough to protect continence and erectile function. PSMA-PET, with its lesion-level spatial resolution, is a credible answer to that problem — for treatment planning, intraoperative targeting, and post-treatment confirmation of margins. If Telix can generate real-world evidence tying imaging to ablation outcomes, it transforms its agents from diagnostic commodities into indispensable workflow infrastructure, and at that point pricing power and repeat utilization both improve substantially.
The risk is that letters of intent are not contracts, and the investigational framing means no near-term revenue. More importantly, the ablative-therapy segment is genuinely nascent in the U.S. — urologists are slow to abandon prostatectomy and radiation, reimbursement for HIFU and TULSA remains inconsistent, and any clinical evidence Telix generates will take years to reach guideline committees. There is also competitive exposure: Lantheus, which markets PYLARIFY and holds the other major slice of PSMA-PET volume, has every incentive to pursue identical partnerships the moment these collaborations show traction.
The single number worth watching is EDAP’s installed base growth rate for Focal One. If that accelerates through 2026, it validates the market Telix is entering; if it stalls, the imaging collaboration becomes an elegant story with no commercial floor beneath it.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
